In late 2014, Paris, France-based Neovacs reported a midstage clinical trial failure and took a big share price hit. Following that, it shifted its focus to a separate candidate—IFNα-Kinoid for the treatment of lupus—and this week entered a public funding agreement that may assist it in commercializing that vaccine.
Read more and add your comments.
“Glad you are out of the hospital and I hope you are feeling better. red”
““Advocate” is one of those terms I hear tossed around a lot, by my clients, by other professionals, and in…”
“Okay so... fml. I thought I could do a little fitness an voila but no... that's not real life. I've…”
You make all the difference.
We'll make all the badges.